Navigation Links
Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Date:10/4/2010

dates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and

Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. FDA for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA approved labeling for the products, and not the information discussed in this news release.CONTACT: AmgenAshleigh Koss: +1 (805) 313-6151 (U.S. media)Carrie Deverell: +41 41 3690 308 (E.U. media)Sabrina Paiva: +1 (905) 285-3145 (Canada media)Arvind Sood: +1 (805) 447-1060 (investors)(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGE
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Conferee ... for Topics for Conferee Networking. These two-hour sessions provide ... to meet and resolve problems, discuss new techniques, or ... deadline to submit a topic for consideration is August ... pittcon.org . The Conferee Networking committee will review the ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... PharmaVentures announced today that it was delighted to act ... Canada as Merck & Co) to secure its deal with ... Roslin BioCentre, for the former MSD research facility in Newhouse, ... MSD, the Scottish Life Sciences community and the Scottish Government. ...
...   Reportlinker.com announces that a new market ... , Strategic Analysis of the Collagen ... http://www.reportlinker.com/p0760990/Strategic-Analysis-of-the-Collagen-Peptide-Market-in-the-United-States.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biomaterial This ... peptides. The historical period is from 2007, ...
... MECHANICSBURG, Pa., Jan. 18, 2012  Select Medical announced it ... Specialists, a well-known provider of physical therapy in the ... Select Medical family with a 25-year reputation for providing ... First Choice and another Select Medical brand known as ...
Cached Biology Technology:PharmaVentures Helps Secure Investor for Former MSD Research Site 2Strategic Analysis of the Collagen Peptide Market in the United States 2First Choice Rehabilitation Specialists Joins Select Medical 2
(Date:7/24/2014)... of how wildlife loss leads to conflict among people ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis of ... an interdisciplinary approach to tackle global biodiversity decline. , ... of the world,s people and provides protein for more ... come as no surprise that today,s unprecedented loss of ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... Acoustic disturbance has different effects on different species ... the Universities of Bristol and Exeter which tested ... sooner to a flying seagull predator model when ... observed in European minnows. , Lead author ... Sciences said: "Noise levels in many aquatic environments ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Finland, have identified a blood-flow glucose consumption mismatch that ... study published in Clinical Cancer Research , a ... Based on these findings, they suggested that the ... important information about a tumor than just looking at ...
... can monitor chemical processes or equipment activity and then ... many facilities that could benefit from the use of ... instead, because the reliability, speed and security of the ... needs. The U.S. Department of Energy,s Savannah ...
... forest the boreal forest across large stretches of ... increasing threat, a team of international researchers has found. ... Canada, University of Adelaide in Australia and the National ... of existing boreal forests in order to secure biodiversity ...
Cached Biology News:Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness 2SRNL, automakers to develop high-performance wireless sensors networks 2SRNL, automakers to develop high-performance wireless sensors networks 3World's last great forest under threat: New study 2